SpyGlass Pharma Acquired Advanced Vision Science
The Irvine-based pharmaceutical company purchased the intraocular lens manufacturer for $13 million.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Do you believe corporate acquisitions in the medical device industry benefit the average patient?
SpyGlass Pharma has acquired 100% of the outstanding shares of Advanced Vision Science in an all-cash deal worth approximately $13 million. This strategic move allows the Irvine firm to secure manufacturing capacity for its clinical drug delivery programs.
Why it matters
The acquisition secures essential supply chain capabilities for SpyGlass Pharma as it seeks to scale the production of intraocular lenses paired with its proprietary drug delivery pads. This vertical integration supports the company's ongoing Phase 3 clinical trials.
SpyGlass Pharma completed the $13 million acquisition of Advanced Vision Science, a manufacturer with a history dating back to 1975. The deal grants SpyGlass full control over the firm that provides lenses for its current Phase 3 clinical trials.
The players
SpyGlass Pharma
Headquartered in Irvine, this company focuses on developing drug delivery technologies for the eyes.
Advanced Vision Science
This manufacturer specializes in ophthalmic devices and intraocular lens technology.
Santen Pharmaceutical
This global ophthalmic company previously held Advanced Vision Science as a wholly owned subsidiary.
Bausch + Lomb
This major eye health products company will continue to license hydrophobic acrylic lens material from the acquired firm.
The details
SpyGlass Pharma acquired all common stock of Advanced Vision Science, which previously operated as a wholly owned subsidiary of Santen Pharmaceutical. The acquired entity maintains a manufacturing facility registered with both the U.S. FDA and the Japanese Ministry of Health to produce medical ophthalmic devices.
Timeline
1975 marked the start of manufacturing operations for Advanced Vision Science.
July 2008 saw the company launch its foldable lens product line in Japan.
October 01, 2026, served as the formal announcement date for the acquisition.
Market Landscape
This acquisition reflects a broader industry movement toward vertical integration, where pharmaceutical firms secure in-house manufacturing for specialized medical components. By bringing Advanced Vision Science under its control, SpyGlass Pharma mitigates supply risks against larger market rivals.
Patients participating in SpyGlass Pharma's clinical trials may see improved consistency in the development and availability of their treatment devices. For the broader market, the transition ensures that existing commercial supply contracts for lens materials remain stable under the new ownership.
The takeaway
Vertical integration remains a critical lever for biotech firms looking to transition from clinical development to commercial readiness. Securing ownership of essential hardware allows companies to maintain tighter control over their product roadmaps and long-term production stability.
Further reading
For more on industry developments, see our Healthcare sector coverage.
Live Poll
Do you believe corporate acquisitions in the medical device industry benefit the average patient?
